Trial Profile

A phase 1 study to to evaluate the safety of APAC in chronic kidney disease patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antiplatelet and anticoagulant therapeutic Aplagon (Primary)
Indications Renal failure
Focus Adverse reactions; First in man
Sponsors Cadila Pharmaceuticals

Most Recent Events

03 Feb 2025 According to Aplagon media release, company is looking forward to announcing clinical results from this trial in 2025 and 2026.
03 Feb 2025 According to Aplagon media release, APAC is poised to complete this trial in 2025
11 Nov 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com